The company has already filed for international patent for this drug in the US, Canada and some countries in Europe, Latin America and Asia. The launch is planned in the following quarter.
The company is also targeting a launch of about 20 products in the next year which are in different stages of the clinical trials and bio-equivalence studies. These new products cover the therapeutic segments of cardiology, diabetology and neurology. Two products each would be launched from these segments in the next financial year. Three products would be launched in the anti-cancer segment and one each in anti-asthmatic, anti-alcoholic, anti-diarroheal segments. Ind-Swift is also looking to further strengthen the marketing network to help attain higher growth levels.
Ind-Swift Limited recorded a turnover of Rs 135.95 crore with a net profit of Rs 8.41 crore for the first nine months of the current year against sales of Rs 147.86 with a net profit of Rs 8.32 crore for the 12 months of the previous year.